Warfarin (Coumadin®, Jantoven®) has been the mainstay of oral anticoagulant ("blood thinning") therapy for more than 50 years. Though an effective therapy, warfarin’s challenges are well-known, such as the need for frequent monitoring and dosage adjustments and its sensitivity to diet and lifestyle factors.
Three new oral anticoagulants have been FDA approved over the past three years: apixaban (Eliquis®), dabigatran (Pradaxa®), and rivaroxaban (Xarelto®). Each of these new oral anticoagulants have both advantages and disadvantages compared to warfarin.
To assist patients understanding of the anticoagulant options now available, Clot Connect has created a two-page handout “Comparison of oral blood thinners”. The handout is available as a .pdf at this link.